Tower Research Capital LLC TRC Purchases 5,972 Shares of Cabot Co. (NYSE:CBT)

Tower Research Capital LLC TRC lifted its holdings in Cabot Co. (NYSE:CBT - Free Report) by 225.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,617 shares of the specialty chemicals company's stock after buying an additional 5,972 shares during the period. Tower Research Capital LLC TRC's holdings in Cabot were worth $787,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new position in Cabot in the 4th quarter valued at $26,000. EverSource Wealth Advisors LLC grew its position in Cabot by 37.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company's stock valued at $74,000 after buying an additional 219 shares during the period. GAMMA Investing LLC increased its holdings in Cabot by 10.7% during the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company's stock worth $123,000 after buying an additional 130 shares during the last quarter. Manchester Capital Management LLC raised its position in Cabot by 1,685.1% in the fourth quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company's stock worth $153,000 after acquiring an additional 1,584 shares during the period. Finally, KBC Group NV boosted its stake in Cabot by 43.1% in the fourth quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company's stock valued at $187,000 after acquiring an additional 616 shares during the last quarter. 93.18% of the stock is owned by institutional investors.

Cabot Stock Performance

CBT traded up $1.61 on Friday, hitting $78.83. The company's stock had a trading volume of 151,083 shares, compared to its average volume of 431,749. The company's 50 day simple moving average is $81.33 and its 200-day simple moving average is $92.88. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. Cabot Co. has a 12 month low of $73.63 and a 12 month high of $117.46. The firm has a market cap of $4.27 billion, a P/E ratio of 10.47, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Analysts forecast that Cabot Co. will post 7.57 EPS for the current year.

Analyst Ratings Changes

CBT has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their price target on shares of Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a report on Friday, February 21st. StockNews.com upgraded Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th. Mizuho cut their price target on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, UBS Group decreased their price objective on Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a report on Monday, April 7th.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.